Through an in-depth immune analysis of 60 previously vaccinated patients with advanced NSCLC, we reveal that UCPVax induces highly polyfunctional (polyF) CD4+ Th1 cells with cytolytic properties, generates robust UCP-specific antibody (Ab) responses, and promotes strong epitope spreading—factors that contribute to optimal tumor control. The gene discussed is CD4; the disease is neoplasm.